Indicated for the treatment of adult patients with: 🔹 Ovarian Cancer: Maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. 🔹 Breast Cancer: Germline BRCA-mutated, HER2-negative metastatic breast cancer. 🔹 Pancreatic Cancer: Maintenance treatment for metastatic pancreatic cancer (gBRCA mutated). 🔹 Prostate Cancer: Metastatic castration-resistant prostate cancer with HRR gene mutations.

Dosage and administration

Packaging: 150 mg film-coated tablets. ⚠️ ADMINISTRATION PROTOCOL (Tablets): Recommended Dose: 300 mg taken twice daily. Per Dose: Take 2 tablets (150 mg each) in the morning and 2 in the evening. Total Daily Dose: 600 mg. Food Intake: Can be taken with or without food. Administration: Swallow tablets whole. Do not chew, crush, or split.

Hypersensitivity to Olaparib. Pregnancy and breastfeeding (embryo-fetal toxicity). Severe renal or hepatic impairment.

Common adverse reactions include: 🩸 Blood: Anemia (low hemoglobin), neutropenia, thrombocytopenia. Monthly blood tests are required. 📉 Digestive: Nausea, vomiting, fatigue, diarrhea, dysgeusia (taste changes). 🌀 Respiratory: Dyspnea (shortness of breath), cough. Patients should monitor for signs of fatigue and weakness.

Olanib 150 — Olaparib 150 mg, 120 pcs, Everest

100% original product

Active ingredient

Olaparib

Manufacturer

Everest

Dosage 150 mg

Dosage form Tablets

Tablets per pack 120

Olanib 150 (Olaparib) 150 mg Tablets

Name: Olanib 150
Brand: Everest
SKU: PROD-145
Price: 37313 UAH
Availability: InStock

37313₴ ~~41752₴~~ -11%

Olanib 150 mg (Olaparib) is a tablet formulation of the PARP inhibitor used in targeted oncology treatment.

Manufacturer: Everest Pharmaceuticals. Each pack contains 120 tablets. It works by inhibiting poly (ADP-ribose) polymerase (PARP) enzymes, leading to the destruction of cancer cells with damaged DNA repair mechanisms (such as BRCA mutations).

Important Note:

Olanib tablets have different bioavailability compared to capsules. Do not substitute tablets for capsules on a mg-to-mg basis.

Indicated for the treatment of adult patients with:

🔹 Ovarian Cancer: Maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
🔹 Breast Cancer: Germline BRCA-mutated, HER2-negative metastatic breast cancer.
🔹 Pancreatic Cancer: Maintenance treatment for metastatic pancreatic cancer (gBRCA mutated).
🔹 Prostate Cancer: Metastatic castration-resistant prostate cancer with HRR gene mutations.

Packaging: 150 mg film-coated tablets.

⚠️ ADMINISTRATION PROTOCOL (Tablets):

Recommended Dose: 300 mg taken twice daily.
Per Dose: Take 2 tablets (150 mg each) in the morning and 2 in the evening.
Total Daily Dose: 600 mg.
Food Intake: Can be taken with or without food.
Administration: Swallow tablets whole. Do not chew, crush, or split.

Hypersensitivity to Olaparib.
Pregnancy and breastfeeding (embryo-fetal toxicity).
Severe renal or hepatic impairment.

Common adverse reactions include:

🩸 Blood: Anemia (low hemoglobin), neutropenia, thrombocytopenia. Monthly blood tests are required.
📉 Digestive: Nausea, vomiting, fatigue, diarrhea, dysgeusia (taste changes).
🌀 Respiratory: Dyspnea (shortness of breath), cough.
Patients should monitor for signs of fatigue and weakness.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 16.04.2026